相关临床试验
245
33 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1852
进行中（未招募）
12
4.9%
已完成
176
71.8%
Enrolling By Invitation
2
0.8%
尚未招募
19
7.8%
招募中
13
5.3%
终止
9
3.7%
Unknown
5
2.0%
撤回
9
3.7%
暂无批准数据
- MaineHealth is doubling enrollment to 60 patients in the second year of a five-year, $20.7 million NIH-funded study on post-treatment Lyme disease syndrome. - The research aims to determine why 5% to 20% of Lyme patients develop chronic symptoms including fatigue, cognitive difficulties, and joint pain. - Scientists will investigate bacterial strain differences, immune response, genetics, and potential biomarkers as drivers of persistent illness. - The study ensures all participants have confirmed Lyme diagnoses, addressing a key limitation of prior research where patient infection status was uncertain.
- Hopewell Therapeutics has entered its first commercial sublicense agreement with Foxcroft Therapeutics, granting global access to proprietary tissue-targeting lipid nanoparticles for cancer vaccine delivery. - The collaboration builds on Foxcroft's exclusive license to novel tumor lysate-based cancer vaccine technology from Tufts University, with Hopewell's LNPs serving as the preferred delivery system. - Foxcroft plans to initiate large mammal canine trials in mid-2026 using Hopewell's tissue-targeting LNPs, marking a significant step toward human clinical testing. - The sublicense agreement includes substantial financial terms with up to $100 million in sales-based milestone payments, reflecting the commercial potential of the partnership.
- Researchers at Mass General Brigham developed Matrix-Inverse Targeting (MINT) nanoparticles that selectively target damaged cartilage areas in osteoarthritis by leveraging natural biochemical changes in diseased tissue. - The nanoparticles delivered ghrelin mRNA therapy directly to cartilage lesions, reducing cartilage breakdown, limiting bone thickening, and decreasing inflammatory signals in mouse models. - This disease-responsive delivery system automatically adjusts targeting based on damage severity and could support delivery of various RNA-based treatments for osteoarthritis. - The approach avoids complex engineering by using natural tissue changes and aligns with current clinical practices for joint injections, potentially transforming treatment of cartilage loss.
- A Tufts University study analyzing 49 hospitalized patients reveals that those with prominent negative symptoms like social withdrawal and low motivation respond best to Cobenfy (xanomeline-trospium), showing improvements in mood and social engagement. - Patients with aggression or bipolar features saw little benefit from the new drug combination, while those with stimulant use history showed particularly strong responses. - The findings support the concept of biologically distinct psychosis subgroups and represent an early step toward precision psychiatry for treating schizophrenia and related disorders.
- Bondia™, a first-in-class synbiotic medical food, reduced bone loss in the femoral neck by 85% in postmenopausal women with osteopenia compared to placebo in a landmark clinical trial. - The breakthrough study published in Osteoporosis International represents the largest-ever probiotic medical food trial for bone health, following 286 postmenopausal women. - New mechanistic research published in the Journal for Functional Foods demonstrates how Bondia™ strengthens gut barrier integrity, reduces inflammation, and directly inhibits bone-resorbing osteoclast activity. - The National Institute on Aging is funding an 18-month clinical trial (STARS) involving 220 women aged 60 and above to further validate Bondia™'s efficacy in managing bone loss.
- University of Houston's Gregory Cuny received nearly $4 million from the National Institute of Allergy and Infectious Diseases to develop treatments for Cryptosporidium infections, which currently have no effective cure. - Cryptosporidium parasites kill over 50,000 children under five annually through severe diarrhea and represent the second leading cause of diarrhea-related death after rotavirus. - The research targets CDPK1 enzyme, which is essential for parasite survival, with drug candidates designed for gastrointestinal targeting through enterohepatic recycling. - The multi-institutional team aims to establish CDPK1 as a validated drug target while minimizing systemic exposure through direct gastrointestinal tract delivery.
- Japanese scientists have initiated clinical trials for a groundbreaking drug that could enable humans to regrow missing or damaged teeth by targeting the USAG-1 protein. - The therapy works by suppressing USAG-1, a protein that limits tooth growth, with successful preclinical results demonstrated in mice and ferrets. - Initial human trials will test 30 men aged 30-64 missing at least one tooth, with plans to expand to children with congenital tooth absence if proven safe. - Researchers aim to make the treatment available to the general public by 2030, potentially revolutionizing dental care for millions worldwide.
- Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS). - The study combines two doses of psilocybin with integrated therapy sessions and fMRI neuroimaging to explore how the psychedelic modulates interoception and gut-brain communication pathways. - The research addresses the hypothesis that IBS may result from "somatic encoding" of early-life trauma, potentially offering new therapeutic pathways for millions of patients who find no relief through conventional treatments. - This pioneering work represents a paradigm shift toward addressing root psychosomatic causes rather than merely treating symptoms in functional gastrointestinal disorders.
- The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. - North Carolina State University is exploring a novel treatment approach for oral cancer in cats. - Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. - Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.
- Biophytis has received FDA authorization to launch SARA-31, marking the first-ever Phase 3 clinical trial specifically designed to treat sarcopenia, an age-related muscle wasting condition. - The study will evaluate Sarconeos (BIO101) in approximately 900 patients over 65 with severe sarcopenia, measuring the drug's ability to prevent major mobility disability over 12-36 months of treatment. - This regulatory milestone follows promising Phase IIb results where patients receiving the highest dose showed meaningful improvement in the 400-meter walk test, meeting the study's primary endpoint. - The authorization addresses a significant unmet medical need, as sarcopenia affects 10-16% of elderly populations globally and currently lacks effective pharmaceutical treatments.
